These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31752850)

  • 1. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up.
    Jeong HS; Hong SJ; Son S; An H; Kook H; Joo HJ; Park JH; Yu CW; Lim DS
    Cardiovasc Diabetol; 2019 Nov; 18(1):162. PubMed ID: 31752850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
    Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
    Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.
    Vallejo-Vaz AJ; Kondapally Seshasai SR; Kurogi K; Michishita I; Nozue T; Sugiyama S; Tsimikas S; Yoshida H; Ray KK
    Atherosclerosis; 2015 Aug; 241(2):409-18. PubMed ID: 26074315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis.
    Lim JW; Jeong HS; Hong SJ; Kim HJ; Kim YC; Kang BG; Jeon SM; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW
    Heart Vessels; 2019 Jan; 34(1):62-73. PubMed ID: 30047013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J; Shao Y; Liu Y; Tao J
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
    Arnaboldi L; Corsini A
    Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
    Park JB; Jung JH; Yoon YE; Kim HL; Lee SP; Kim HK; Kim YJ; Cho GY; Sohn DW
    Trials; 2017 Oct; 18(1):501. PubMed ID: 29078817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study.
    Na E; Cho S; Kim DJ; Choi J; Han E
    Cardiovasc Diabetol; 2020 May; 19(1):67. PubMed ID: 32416728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.
    Lee HY; Cho HJ; Kim HY; Jeon HK; Shin JH; Kang SM; Baek SH
    Korean J Intern Med; 2014 Nov; 29(6):754-63. PubMed ID: 25378974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia.
    Daido H; Horikawa Y; Takeda J
    Diabetes Res Clin Pract; 2014 Dec; 106(3):531-7. PubMed ID: 25458331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies.
    Chapman MJ; Orsoni A; Robillard P; Hounslow N; Sponseller CA; Giral P
    Curr Med Res Opin; 2014 May; 30(5):775-84. PubMed ID: 24328357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin diabetogenicity: guidance for clinicians.
    Ray K
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetogenic Action of Statins: Mechanisms.
    Carmena R; Betteridge DJ
    Curr Atheroscler Rep; 2019 Apr; 21(6):23. PubMed ID: 31037345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.